Year-end Sale % OFF 
Abstract
Given evidence of chronic inflammation in bipolar disorder (BD), we tested the efficacy of aspirin and minocycline as augmentation therapy for bipolar depression. Ninety-nine depressed outpatients with BD were enrolled in a 6 week, double-blind, placebo-controlled trial, and randomized to one of four groups: active minocycline (100 mg b.i.d.) + active aspirin (81 mg b.i.d.) (M + A); active minocycline + placebo aspirin (M + P); placebo-minocycline + active aspirin (A + P); and placebo-minocycline + placebo aspirin (P + P). A blinded interim analysis mid-way through the study led to the dropping of the M + P and A + P arms from further enrollment giving numbers per group who were included in the final analysis of: 30 (M + A), 18 (M + P), 19 (A + P), and 28 (P + P). When the study started, there were three primary outcome measures. Based on the results of the interim analysis, the primary outcome variable, response to treatment as defined by >50% decrease in Montgomery–Äsberg Depression Rating Scale (MADRS) score was maintained. The other two (i.e., the change in mean MADRS score from baseline to end of study and the remission rate, with remission being defined as a score of <11 on the MADRS) were reduced to exploratory outcome measures because the interim analysis indicated that the study was adequately powered to test differences in response rate but not the mean change in MADRS scores or remission rates. CRP and IL-6 were assayed to measure inflammation. Urinary thromboxane B2 (11-D-TXB2) concentrations, which were significantly increased at baseline in the combined BD sample (n = 90) vs. a healthy control group (n = 27), served as an indirect marker of cyclooxygenase (COX) activity. In a two-group analysis, the M + A group showed a greater response rate than the P + P group (p(one-tailed) = 0.034, OR = 2.93, NNT = 4.7). When all four arms were included in the analysis, there was a main effect of aspirin on treatment response that was driven by both the M + A and the A + P groups (p(two-tailed) = 0.019, OR = 3.67, NNT = 4.0). Additionally, there was a significant 3-way interaction between aspirin, minocycline, and IL-6, indicating that response to minocycline was significantly greater in participants in the M + P group with higher IL-6 concentrations. Further, participants in the M + P group who responded to treatment had significantly greater decreases in IL-6 levels between baseline and visit 7 vs. non-responders. Regarding the exploratory outcomes, there was a main effect for aspirin on the remission rate (χ12 = 4.14, p(2t) = 0.04, OR = 2.52, NNT = 8.0). There was no significant main effect of aspirin or minocycline on the mean change in MADRS score across visits. Aspirin and minocycline may be efficacious adjunctive treatments for bipolar depression. Given their potential import, additional studies to confirm and extend these findings are warranted.
Highlights
The treatment of bipolar depression is a major clinical challenge and no conventional antidepressants have been approved by the FDA for the short-term treatment of bipolar depression[1]
Three pharmacotherapies are FDA-approved for bipolar depression; the combination of olanzapine and fluoxetine (OF), quetiapine monotherapy (QTP), and lurasidone as a monotherapy or adjunctive therapy
The design was adapted by stopping future enrollment into the A + P and M + P groups and instead randomization of all future participants was to the M + A or P + P groups, resulting in the numbers per group included in the final statistical analyses of: 30 (M + A), 18 (M + P), 19 (A + P), and 28 (P + P)
Summary
The treatment of bipolar depression is a major clinical challenge and no conventional antidepressants have been approved by the FDA for the short-term treatment of bipolar depression[1]. Three pharmacotherapies are FDA-approved for bipolar depression; the combination of olanzapine and fluoxetine (OF), quetiapine monotherapy (QTP), and lurasidone as a monotherapy or adjunctive therapy. These treatments produce numbers needed to treat (NNT) for response of 4 for OF, 6 for QTP, and 5–7 for lurasidone, respectively[2], and all three produce significant side-effects with numbers need to harm (NNH) of 6 for OF (e.g., weight gain), 5 for QTP (e.g., sedation), and 15–16 for lurasidone (e.g., akathisia and nausea), respectively[2]. Two promising candidates are minocycline and low-dose aspirin, as reviewed in the initial published protocol[8] and summarized here: both medications are well-tolerated, even with long-term use, well absorbed and brain penetrant, and likely exert antiinflammatory effects in the brain and the periphery
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
